References: 1. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756-760, 2006
2. Bastien JI, McNeill KA, Fine HA: Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer 121:502-516, 2015
3. Batchelor TT, Mulholland P, Neyns B, Nabors LB, Campone M, Wick A, et al: Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212-3218, 2013
4. Best MG, Sol N, Zijl S, Reijneveld JC, Wesseling P, Wurdinger T: Liquid biopsies in patients with diffuse glioma. Acta Neuropathol 129:849-865, 2015
5. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al: Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra224, 2014
6. Chamberlain MC: Treatment of newly diagnosed malignant glioma in the elderly people: new trials that impact therapy. Int J Clin Pract 67:1225-1227, 2013
7. Chan KC, Jiang P, Zheng YW, Liao GJ, Sun H, Wong J, et al: Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem 59:211-224, 2013
8. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
9. Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF: Pros and cons of current brain tumor imaging. Neuro Oncol 16 Suppl 7:vii2-11, 2014
10. Ellis HP, Greenslade M, Powell B, Spiteri I, Sottoriva A, Kurian KM: Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Disease, and Models to Predict Disease Recurrence. Front Oncol 5:251, 2015
11. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al: Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354, 2000
12. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014
13. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
14. Idbaih A, Omuro A, Ducray F, Hoang-Xuan K: Molecular genetic markers as predictors of response to chemotherapy in gliomas. Curr Opin Oncol 19:606-611, 2007
15. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM: Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99:1047-1052, 2003
16. Khwaja FW, Reed MS, Olson JJ, Schmotzer BJ, Gillespie GY, Guha A, et al: Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients. J Proteome Res 6:559-570, 2007
17. Kros JM, Mustafa DM, Dekker LJ, Sillevis Smitt PA, Luider TM, Zheng PP: Circulating glioma biomarkers. Neuro Oncol 17:343-360, 2015
18. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al: Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med 4:162ra154, 2012
19. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al: Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67, 2006
20. Lonardi S, Tosoni A, Brandes AA: Adjuvant chemotherapy in the treatment of high grade gliomas. Cancer Treat Rev 31:79-89, 2005
21. Macarthur KM, Kao GD, Chandrasekaran S, Alonso-Basanta M, Chapman C, Lustig RA, et al: Detection of brain tumor cells in the peripheral blood by a telomerase promoter-based assay. Cancer Res 74:2152-2159, 2014
22. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L: Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275-287, 2007
23. McPherson CM, Gerena-Lewis M, Breneman JC, Warnick RE: Results of phase I study of a multi-modality treatment for newly diagnosed glioblastoma multiforme using local implantation of concurrent BCNU wafers and permanent I-125 seeds followed by fractionated radiation and temozolomide chemotherapy. J Neurooncol 108:521-525, 2012
24. Miknyoczki S, Chang H, Grobelny J, Pritchard S, Worrell C, McGann N, et al: The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290-2302, 2007
25. Mourad PD, Farrell L, Stamps LD, Chicoine MR, Silbergeld DL: Why are systemic glioblastoma metastases rare? Systemic and cerebral growth of mouse glioblastoma. Surg Neurol 63:511-519; discussion 519, 2005
26. Muller C, Holtschmidt J, Auer M, Heitzer E, Lamszus K, Schulte A, et al: Hematogenous dissemination of glioblastoma multiforme. Sci Transl Med 6:247ra101, 2014
27. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, et al: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497:108-112, 2013
28. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C: Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35-61, 1997
29. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol 16 Suppl 4:iv1-63, 2014
30. Peschillo S, Caporlingua A, Diana F, Caporlingua F, Delfini R: New therapeutic strategies regarding endovascular treatment of glioblastoma, the role of the blood-brain barrier and new ways to bypass it. J Neurointerv Surg, 2015
31. Preusser M: Neuro-oncology: a step towards clinical blood biomarkers of glioblastoma. Nat Rev Neurol 10:681-682, 2014
32. Purow BW, Schiff D: Glioblastoma genetics: in rapid flux. Discov Med 9:125-131, 2010
33. Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26:186-197, 2007
34. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell 20:810-817, 2011
35. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al: Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318:287-290, 2007
36. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009
37. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
38. Sullivan JP, Nahed BV, Madden MW, Oliveira SM, Springer S, Bhere D, et al: Brain tumor cells in circulation are enriched for mesenchymal gene expression. Cancer Discov 4:1299-1309, 2014
39. Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, et al: Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proc Natl Acad Sci U S A 109:3041-3046, 2012
40. Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, et al: Molecular diagnostics of gliomas: the clinical perspective. Acta Neuropathol 120:585-592, 2010
41. Tanaka S, Louis DN, Curry WT, Batchelor TT, Dietrich J: Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end? Nat Rev Clin Oncol 10:14-26, 2013
42. Thomas AA, Brennan CW, DeAngelis LM, Omuro AM: Emerging therapies for glioblastoma. JAMA Neurol 71:1437-1444, 2014
43. Villano JL, Seery TE, Bressler LR: Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64:647-655, 2009
44. von Deimling A, Korshunov A, Hartmann C: The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations. Brain Pathol 21:74-87, 2011
45. Williams M, Liu ZW, Woolf D, Hargreaves S, Michalarea V, Menashy R, et al: Change in platelet levels during radiotherapy with concurrent and adjuvant temozolomide for the treatment of glioblastoma: a novel prognostic factor for survival. J Cancer Res Clin Oncol 138:1683-1688, 2012
46. Wilson TA, Karajannis MA, Harter DH: Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int 5:64, 2014
47. Ziegler DS, Kung AL, Kieran MW: Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26:493-500, 2008